The Freshfields team was led by corporate partners Teresa Ko, Calvin Lai and Richard Wang.

Freshfields Bruckhaus Deringer LLP ('Freshfields') has advised a consortium of 14 bookrunners on the US$1.8 billion global offering of China Resources Pharmaceutical Group Limited ('CR Pharmaceutical'), acting as US and Hong Kong counsel to the underwriters of the deal. The shares commenced trading on the Hong Kong Stock Exchange on 28 October 2016.

The initial offering contained 1,543,141,500 shares at a price of HK$9.1 per share and is the second largest IPO to take place in Hong Kong during 2016.

CR Pharmaceutical, the leading integrated pharmaceutical company, is the second largest pharmaceutical manufacturer and pharmaceutical distributor in China, and in particular, the largest manufacturer of OTC drugs in China. It also has three listed subsidiaries in the PRC. The group primarily plans to use the net proceeds to make strategic acquisitions globally, as well as improving its existing logistics network.

The Freshfields team was led by corporate partners Teresa Ko, Calvin Lai and Richard Wang.